{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010114","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.913710+00:00","generated_at":"2026-06-17T13:27:27.054354+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vera Therapeutics reports FY2022 net loss $89.1M; positive atacicept interim data; plans Phase 3 in Q2 2023","bullets":["Positive interim Phase 2b ORIGIN data: 41% mean proteinuria reduction vs baseline at 24 weeks in 150mg dose.","36-week data on track for Q2 2023; Phase 3 initiation planned for Q2 2023.","FY2022 net loss $89.1M ($3.35/share) vs $32.6M ($2.43) prior year.","Cash $114.7M as of Dec 31, 2022; raised ~$107.6M net in Feb 2023 offering.","Prioritizing atacicept for IgAN; funds expected to last to early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010114","json":"https://secwatch.observer/filing/0000950170-23-010114.json","markdown":"https://secwatch.observer/filing/0000950170-23-010114.md","text":"https://secwatch.observer/filing/0000950170-23-010114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023010114/0000950170-23-010114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023010114/vera-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:27:27.054354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8da1519bd2508f609734c1e3e6b8a8e27588b78c","claim":"Vera Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income net loss of $89.1 million, EPS a net loss per diluted share of $3.35.","evidence_excerpt":"For the year ended December 31, 2022, the company reported a net loss of $89.1 million, or a net loss per diluted share of $3.35","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000095017023010114/0000950170-23-010114-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"net loss of $89.1 million"},{"label":"EPS","value":"a net loss per diluted share of $3.35"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}